LA HB766

Requires health insurers providing cancer treatment coverage to cover orally administered anti-cancer medications on terms no less favorable than IV or injected anti-cancer medications

Prohibits insurers from imposing prior authorization, dollar limits, copayments, deductibles, coinsurance, specialty tier placement, or other utilization management requirements on oral anti-cancer drugs that result in greater out-of-pocket costs or more restrictive access than IV/injected alternatives

Bans copayment accumulator and maximizer programs that prevent manufacturer coupons, discounts, or third-party financial assistance from counting toward enrollees' deductibles and out-of-pocket maximums for anti-cancer medications

Prohibits insurers from reclassifying or increasing cost-sharing for anti-cancer medications to achieve compliance with the parity requirements

Expands applicability to include individual and group health plans, high-deductible health plans, qualified health plans on exchanges, nonfederal governmental plans, and the Office of Group Benefits (removing prior exemptions for these plan types)